Premium
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia
Author(s) -
Zheng Hong,
Mineishi Shin,
Claxton David,
Zhu Junjia,
Zhao Chenchen,
Jia Bei,
Ehmann W. Christopher,
Rybka Witold B.,
Naik Seema,
Songdej Natthapol,
Drabick Joseph J.,
Hohl Raymond J.
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26043
Subject(s) - medicine , decitabine , oncology , tolerability , myeloid leukemia , avelumab , chemotherapy , cancer , immunotherapy , adverse effect , nivolumab , biochemistry , gene expression , chemistry , dna methylation , gene